OpenAI Launches GPT-Rosalind for Life Sciences and Drug Discovery

OpenAI unveiled GPT-Rosalind, a specialized frontier reasoning model targeting the life sciences sector. The model is designed to accelerate drug discovery and genomics research by substantially reducing the current 10-15 year development timeline through advanced biochemistry and genomic analysis capabilities while emphasizing human oversight.